Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success. (23rd May 2022)

• Record Type: Journal Article
• Authors: Morrisette, Taylor; Molina, Kyle C; Da Silva, Beatriz; Mueller, Scott W; Damioli, Laura; Krsak, Martin; Miller, Matthew A; Fish, Douglas N
• Is Part Of: Open forum infectious diseases. Volume 9:Number 6(2022)
• Publication Date: 2022-05-23
• Subjects: Gram-positive infections -- long-term tolerability -- tedizolid -- thrombocytopenia; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac028
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Tedizolid has activity against Gram-positive pathogens as well as Mycobacterium spp and Nocardia spp. Real-world evidence supporting long-term tolerability and clinical success of tedizolid is lacking. Prolonged tedizolid therapy (median, 188 days; interquartile range, 62–493 days) appeared to be well tolerated in 37 patients (8.1% experienced adverse effect leading to discontinuation). Clinical success was 81.3% in those evaluated. Abstract : Real-world evidence supporting long-term tolerability and clinical success of tedizolid is lacking. Prolonged tedizolid therapy (median, 188 days; interquartile range, 62–493 days) in 37 patients was well tolerated with few serious adverse effects and good clinical success (81.3%).